Mitochondrial donation is a medical technique designed to prevent transmitting mitochondrial diseases from parents to their children. Since it involves combining genetic material from three individuals, it has raised significant ethical concerns. The UK became the first country to legalize mitochondrial donation in 2015 to prevent mitochondrial disorders. This article will explore how the UK established its regulatory framework for this technique.
What Are Mitochondria?
Mitochondria are tiny cellular organs, or organelles, that produce energy for all of our cells, including the egg cell and the cells of the embryo. Mitochondria have their genetic material, known as mitochondrial DNA, that contains genes for producing energy. With increasing age, these mitochondria can become dysfunctional and produce less energy. It can lead to problems with the egg and can lead to embryos that stop developing.
Errors in mitochondrial DNA can also lead to mitochondrial disorders like Leigh syndrome. Leigh syndrome is the most common childhood mitochondrial disorder, occurring in about 2.5 out of every 100,000 births, and features symptoms like neurodevelopmental regression, muscle weakness, and brain dysfunction (Gorman et al. 2016).
The Science Behind Mitochondrial Donation
One way to potentially overcome these issues is by using a mitochondrial donation. It involves replacing defective mitochondria with healthy ones from a donor while retaining the patient's DNA. There are two main types of mitochondrial donation: pronuclear transfer and spindle transfer.
Mitochondrial donation results in a so−called "three−parent" embryo because it combines genetic material from three individuals: the nuclear DNA from both parents and mitochondrial DNA from the donor. Because of this, mitochondrial donation raises many ethical concerns and is considered a type of human genome modification. It has led many countries worldwide to prohibit the technique. In the UK, the procedure has been legalized to help patients with mitochondrial disorders from passing it on to their children.
Regulatory Frameworks for Mitochondrial Donation in the UK
After the cloning of Dolly the sheep in 1996, there was a lot of interest in how it could apply to human embryology (Craven et al. 2015). A 1998 report by the Human Fertilisation and Embryology Authority (HFEA), the UK regulator for IVF, highlighted the need for updated regulations to include research on preventing mitochondrial diseases. In response, the UK government established an expert group to explore this new area of research. It led to new regulations in 2001 that allowed broader research on human embryos, particularly in developing treatments for mitochondrial diseases.
Early Research & Regulatory Progress
In 2004, a team at Newcastle University in Tyne, England, requested a research license from the HFEA to study pronuclear transfer to prevent mitochondrial disease, which was approved in 2005 (Craven et al. 2015).
In 2010, an advisory committee from the HFEA conducted a review of mitochondrial donation for the prevention of mitochondrial disease. This review resulted in a recommendation to the Government to permit its use in humans (Craven et al. 2015). The UK government then requested expert opinions on the method's safety and effectiveness. The HFEA advisory committee reviewed mitochondrial donation research conducted on non−human primates and human eggs by the Newcastle group and others and found no safety concerns with the procedure.
Ethical Considerations & Public Consultation
The ethics of mitochondrial donation were discussed at length, with a report from the Nuffield Council on Bioethics supporting its use after public review (press release), stating “if these novel techniques are adequately proven to be acceptably safe and effective as treatments, it would be ethical for families to use them.”
There was also a public consultation by the HFEA in 2013. Most concerns focused on safety and ethical issues, but the public generally trusted the experts to manage these risks appropriately. There were also discussions on germline modification, which is a consideration for mitochondrial donation since it involves replacing mitochondrial DNA that can be passed on to children. However, the public recognized the potential benefit of eradicating mitochondrial diseases and considered it more important than the possible risks of germline modification. Overall, the HFEA concluded:
“Our advice to the Government set out in this report − is that there is general support for permitting mitochondria replacement in the UK, so long as it is safe enough to offer in a treatment setting and is done so within a regulatory framework. Despite the strong ethical concerns that some respondents to the consultation expressed, the overall view is that ethical concerns are outweighed by the arguments in favor of permitting mitochondria replacement.”
To read more about the ethical concerns of mitochondrial donation, check out our post Exploring the Ethical Implications of Mitochondrial Donation.
UK Enacts Mitochondrial Donation Regulations into Law
After a review of the information provided by the HFEA, the UK government decided to draft regulations allowing mitochondrial donation in the clinic. In 2015, the Mitochondrial Donation Regulations were signed into law, making mitochondrial donation legal in the UK. The law established the legal guidelines for the clinical application of mitochondrial donation techniques within the UK. The regulations specified two types of mitochondrial donation: maternal spindle transfer and pronuclear transfer. These techniques are regulated through a licensing framework administered by the HFEA.
Clinics that want to perform mitochondrial donation must obtain specific approval from the HFEA, ensuring that mitochondrial donation is conducted safely and within a controlled setting. Furthermore, the HFEA must confirm that the eggs or embryos used in mitochondrial donation carry a significant risk of mitochondrial abnormalities that could lead to severe mitochondrial diseases.
Newcastle Fertility Centre: The First Licensed Clinic for Mitochondrial Donation Worldwide
In 2016, Newcastle Fertility Centre applied for the mitochondrial donation license. It also began recruiting patients for a clinical trial to study the long−term health outcomes of children born through this method. Because of the lack of human data on mitochondrial donation, the UK's National Health System agreed to help fund this clinical trial.
In 2017, Newcastle was awarded the first mitochondrial donation license by the HFEA to allow pronuclear transfer to prevent mitochondrial disease transmissions in patients. Newcastle estimates that about 25 patients will be treated annually following the clinical trial. The first live births from the trial were reported in 2023.
IFG: Tailored Mitochondrial Donation Programs
International Fertility Group (IFG) is a remarkable agency choice due to our unwavering commitment to patient−centered care, ongoing research, and the implementation of the latest medical advancements. Our comprehensive services include a wide range of assisted reproductive technologies; thus, mitochondrial donation allows us to combine genetic material from both parents and donors, enabling families to conceive healthy children while reducing the risk of hereditary mitochondrial disorders.
Our team of seasoned specialists works collaboratively to guide patients through the process. We understand the emotional and physical challenges that can arise during fertility treatments, which is why we prioritize compassionate support alongside our advanced medical expertise!
Conclusions
Mitochondrial donation is a technique that replaces unhealthy mitochondria in an egg cell or embryo with healthy ones from a donor. This process has sparked ethical debates and regulatory challenges because of concerns over germline modification.
However, the UK has implemented laws and guidelines for the safe usage of this treatment in licensed clinics. After thorough research and public opinion confirming its safety and benefits, the Newcastle Fertility Centre became the first to receive a license for this treatment. This technology provides options for families at risk of mitochondrial diseases, offering them the chance to have healthy children.
